BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Farber M, Chen Y, Arnold L, Möllmann M, Boog-Whiteside E, Lin YA, Reinhardt HC, Dührsen U, Hanoun M. Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosis. Sci Rep 2021;11:22062. [PMID: 34764342 DOI: 10.1038/s41598-021-01300-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Lee J, Liu S, Wang Y, Liang Y, Jablons DM. MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway. Oncotarget 2022;13:1217-1236. [DOI: 10.18632/oncotarget.28305] [Reference Citation Analysis]
2 Zhong X, Ma H. Targeting CD38 for acute leukemia. Front Oncol 2022;12:1007783. [DOI: 10.3389/fonc.2022.1007783] [Reference Citation Analysis]
3 Mustafa N, Azaman MI, Ng GGK, Chng WJ. Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies. Biomolecules 2022;12:1261. [DOI: 10.3390/biom12091261] [Reference Citation Analysis]
4 Szlasa W, Czarny J, Sauer N, Rakoczy K, Szymańska N, Stecko J, Kołodziej M, Kaźmierczak M, Barg E. Targeting CD38 in Neoplasms and Non-Cancer Diseases. Cancers 2022;14:4169. [DOI: 10.3390/cancers14174169] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Maynard RS, Hellmich C, Bowles KM, Rushworth SA. Acute Myeloid Leukaemia Drives Metabolic Changes in the Bone Marrow Niche. Front Oncol 2022;12:924567. [DOI: 10.3389/fonc.2022.924567] [Reference Citation Analysis]